乌鸦传媒

But the best strategy for stage I disease is less clear, experts say

Challenges include identifying high-risk patients and optimizing therapy

Transformation occurs in a minority of patients, with an extremely poor prognosis

"It is really a discussion of their individual health conditions," one expert says

Two new drugs offer promise after obeticholic acid misses out on full approval

Disease chronicity and progression raise ongoing questions

More research needed on role of local therapy in new era of treatment

Balancing risk and benefit takes a personal approach with frailty scores, clinical assessments

Expert insights into clinical progress and future perspectives

New research focuses on interventions for highest-risk patients

Though only one approved agent has been available for decades, the armamentarium has expanded

A major reason for the increase in prevalence is increased survival from improved management

While all adults age 75 and up are eligible, here's who's considered high risk in the 60-74 group

"Remarkable" how closely effectiveness in real-world setting matches clinical trial efficacy